Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study.
BACKGROUND
About two-thirds of the excess familial risk associated with breast cancer is still unaccounted for and may be explained by multiple weakly predisposing alleles. A gene thought to be involved in low-level predisposition to the disease is ERBB2 (HER2). This gene is involved in cell division, differentiation, and apoptosis and is frequently amplified in breast tumours. Its amplification correlates with poor prognosis. Moreover, the coding polymorphism I655V has previously been associated with an increased risk of breast cancer.


METHODS
We aimed to determine if common polymorphisms (frequency >or= 5%) in ERBB2 were associated with breast cancer risk in a white British population. Five single-nucleotide polymorphisms (SNPs) were selected for study: SNP 1 near the promoter, SNP 2 in intron 1, SNP 3 in intron 4, SNP 4 in exon 17 (I655V), and SNP 5 in exon 27 (A1170P). We tested their association with breast cancer in a large case-control study (n = 2192 cases and 2257 controls).


RESULTS
There were no differences in genotype frequencies between cases and controls for any of the SNPs examined. To investigate the possibility that a common polymorphism not included in our study might be involved in breast cancer predisposition, we also constructed multilocus haplotypes. Our set of SNPs generated all existing (n = 6) common haplotypes and no differences were seen in haplotype frequencies between cases and controls (P = 0.44).


CONCLUSIONS
In our population, common ERBB2 polymorphisms are not involved in predisposition to breast cancer.
Benusiglio
Patrick R
PR
Department of Oncology, University of Cambridge, Strangeways Research Laboratories, Cambridge, UK. patrick@srl.cam.ac.uk
Lesueur
Fabienne
F
Luccarini
Craig
C
Conroy
Donald M
DM
Shah
Mitul
M
Easton
Douglas F
DF
Day
Nick E
NE
Dunning
Alison M
AM
Pharoah
Paul D
PD
Ponder
Bruce Aj
BA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D004739:England; D005091:Exons; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D007438:Introns; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics* / Q000502:physiology; D012307:Risk Factors; D044465:White People / Q000235:genetics*
D018719:Erb-b2 Receptor Tyrosine Kinases
J Natl Cancer Inst. 2000 Mar 1;92(5):412-7
10699071
Br J Cancer. 1999 Jul;80 Suppl 1:95-103
10466767
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
11252954
J Natl Cancer Inst. 2001 Apr 4;93(7):557-9
11287454
Cancer Lett. 2001 Nov 8;173(1):37-41
11578807
J Natl Cancer Inst. 2001 Nov 7;93(21):1657-9
11698574
Lancet. 2001 Oct 27;358(9291):1389-99
11705483
Cancer Res. 2001 Dec 1;61(23):8393-4
11731415
Am J Hum Genet. 2002 Feb;70(2):425-34
11791212
Nat Genet. 2002 May;31(1):33-6
11984562
Science. 2002 Jun 21;296(5576):2225-9
12029063
J Natl Cancer Inst. 2002 Dec 4;94(23):1807-8
12464653
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):15937-40
12461170
Lancet. 2003 Mar 8;361(9360):865-72
12642066
J Natl Cancer Inst. 2003 Mar 19;95(6):448-57
12644538
Breast Cancer Res Treat. 2003 Jun;79(3):355-64
12846420
Hum Mol Genet. 2003 Oct 15;12(20):2679-92
12944421
Oncogene. 2003 Sep 29;22(42):6570-8
14528282
Am J Hypertens. 2003 Oct;16(10):859-63
14553966
Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1109-11
14578152
Bioinformatics. 2003 Nov 1;19(16):2147-8
14594722
Am J Hum Genet. 2004 Jan;74(1):106-20
14681826
Am J Hum Genet. 2004 Apr;74(4):610-22
15015130
Oncogene. 1994 Aug;9(8):2269-76
7913545
Br J Cancer. 2000 Nov;83(10):1301-8
11044354